Company intelligence / Profile preview

Purolite

King of Prussia, Pennsylvania, United Statespurolite.com ↗

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Purolite develops and manufactures advanced ion exchange resins and specialty polymers used globally in pharmaceutical/biotech production. Their technologies are critical to the purification of biologics such as monoclonal antibodies and cell/gene therapies. The company’s proprietary bead/resin technologies support both R&D-scale and commercial-scale bioprocesses. They do not develop therapeutics themselves but enable high-quality drug production across many regulated industries. In December 2021 they were acquired by Ecolab for $3.7 billion to strengthen Ecolab’s life sciences division.

Therapeutic areas: Infectious DiseasesImmunologyOncology
Modalities: ProteinMonoclonal antibodyCell therapyGene therapySmall moleculeEnzyme immobilization platforms
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Purolite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purolite.